[1]
Bai B, Jazrawi LM, Kummer FJ, Spivak JM. The use of an injectable, biodegradable calcium phosphate bone substitute for the prophylactic augmentation of osteoporotic vertebrae and the management of vertebral compression fractures. Spine (Phila Pa 1976) 1999; 24: 1521–1526.Google Scholar
[2]
Beckmann J, Ferguson SJ, Gebauer M, Luering C, Gasser B, Heini P. Femoroplasty – augmentation of the proximal femur with a composite bone cement – feasibility, biomechanical properties and osteosynthesis potential. Med Eng Phys 2007; 29: 755–764.CrossrefPubMedWeb of ScienceGoogle Scholar
[3]
Beckmann J, Springorum R, Vettorazzi E, et al. Fracture prevention by femoroplasty – cement augmentation of the proximal femur. J Orthop Res 2011; 29: 1753–1758.Web of ScienceCrossrefPubMedGoogle Scholar
[4]
Belkoff SM, Mathis JM, Erbe EM, Fenton DC. Biomechanical evaluation of a new bone cement for use in vertebroplasty. Spine (Phila Pa 1976) 2000; 25: 1061–1064.Google Scholar
[5]
Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004; 52: 1832–1839.PubMedCrossrefGoogle Scholar
[6]
Cobey JC, Cobey JH, Conant L, Weil UH, Greenwald WF, Southwick WO. Indicators of recovery from fractures of the hip. Clin Orthop Relat Res 1976; 258–262.PubMedGoogle Scholar
[7]
Courtney AC, Wachtel EF, Courtney AC, Wachtel EF, Myers ER, Hayes WC. Age-related reductions in the strength of the femur tested in a fall-loading configuration. J Bone Joint Surg Am 1995; 77: 387–395.Google Scholar
[8]
Egan M, Jaglal S, Byrne K, Wells J, Stolee P. Factors associated with a second hip fracture: a systematic review. Clin Rehabil 2008; 22: 272–282.PubMedWeb of ScienceGoogle Scholar
[9]
Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instruction, and discontinuation. J Manage Care Pharm 1998; 4: 488–492.Google Scholar
[10]
Formiga F, Rivera A, Nolla JM, Coscujuela A, Sole A, Pujol R. Failure to treat osteoporosis and the risk of subsequent fractures in elderly patients with previous hip fracture: a five-year retrospective study. Aging Clin Exp Res 2005; 17: 96–99.CrossrefPubMedGoogle Scholar
[11]
Hananouchi T. Tailor made surgical guide for drilling hole in “femoroplasty”, an augmentation into proximal femur for preventing hip fracture resulted from osteoporosis. Osteoporosis Int 2012; 23: S819–820 [IOF (International Osteoporosis Foundation) Regionals – 3rd Asia-Pacific Osteoporosis Meeting, Kuala Lumpur, Malaysia, December 13–16, 2012].Google Scholar
[12]
Heini PF, Franz T, Fankhauser C, Gasser B, Ganz R. Femoroplasty – augmentation of mechanical properties in the osteoporotic proximal femur: a biomechanical investigation of PMMA reinforcement in cadaver bones. Clin Biomech (Bristol, Avon) 2004; 19: 506–512.CrossrefGoogle Scholar
[13]
Ira P, Scott DL, O’Neill TW, Pritchard C, Woolf AD, Davis MJ. Quality of life, morbidity and mortality after low trauma hip fracture in men. Ann Rheum Dis 2006; 65: 87–92.Google Scholar
[14]
Jensen ME, Evans AJ, Mathis JM, Kallmes DF, Cloft HJ, Dion JE. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects. AJNR Am J Neuroradiol 1997; 18: 1897–1904.PubMedGoogle Scholar
[15]
Kannus P, Parkkari J, Niemi S, et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 2000; 21: 1506–1513.CrossrefGoogle Scholar
[16]
Kessenich CR. Nonpharmacological prevention of osteoporotic fractures. Clin Interv Aging 2007; 2: 263–266.PubMedGoogle Scholar
[17]
Lin JT, Lane JM. Nonpharmacologic management of osteoporosis to minimize fracture risk. Nat Clin Pract Rheumatol 2008; 4: 20–25.PubMedCrossrefGoogle Scholar
[18]
Mortensen L, Charles P, Bekker PJ, et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83: 396–402.Google Scholar
[19]
Nymark T, Lauritsen JM, Ovesen O, Röck ND, Jeune B. Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int 2006; 17: 1353–1357.PubMedCrossrefGoogle Scholar
[20]
Schroder HM, Petersen KK, Erlandsen M. Occurrence and incidence of the second hip fracture. Clin Orthop Relat Res 1993; 289: 166–169.PubMedGoogle Scholar
[21]
Shikinami Y, Okuno M. Bioresorbable devices made of forged composites of hydroxyapatite (HA) particles and poly-l-lactide (PLLA): Part I. Basic characteristics. Biomaterials 1999; 20: 859–877.CrossrefPubMedGoogle Scholar
[22]
Strauss EJ, Pahk B, Kummer FJ, Egol K. Calcium phosphate cement augmentation of the femoral neck defect created after dynamic hip screw removal. J Orthop Trauma 2007; 21: 295–300.CrossrefPubMedWeb of ScienceGoogle Scholar
[23]
Sutter EG, Mears SC, Belkoff SM. A biomechanical evaluation of femoroplasty under simulated fall conditions. J Orthop Trauma 2010; 24: 95–99.PubMedWeb of ScienceCrossrefGoogle Scholar
[24]
Tomita S, Molloy S, Jasper LE, Abe M, Belkoff SM. Biomechanical comparison of kyphoplasty with different bone cements. Spine (Phila Pa 1976) 2004; 29: 1203–1207.Google Scholar
[25]
van der Steenhoven TJ, Schaasberg W, de Vries AC, Valstar ER, Nelissen RG. Augmentation with silicone stabilizes proximal femur fractures: an in vitro biomechanical study. Clin Biomech (Bristol, Avon) 2009; 24: 286–290.Web of ScienceGoogle Scholar
[26]
van der Steenhoven TJ, Schaasberg W, de Vries AC, Valstar ER, Nelissen RG. Elastomer femoroplasty prevents hip fracture displacement. In vitro biomechanical study comparing two minimal invasive femoroplasty techniques. Clin Biomech (Bristol, Avon) 2011; 26: 464–469.Web of ScienceGoogle Scholar
Comments (0)